NewAmsterdam Pharma (NASDAQ:NAMSW – Get Free Report) was the target of a large decrease in short interest during the month of December. As of December 31st, there was short interest totaling 493 shares, a decrease of 73.5% from the December 15th total of 1,861 shares. Based on an average trading volume of 628 shares, the days-to-cover ratio is presently 0.8 days. Based on an average trading volume of 628 shares, the days-to-cover ratio is presently 0.8 days.
Hedge Funds Weigh In On NewAmsterdam Pharma
An institutional investor recently raised its position in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC lifted its stake in NewAmsterdam Pharma (NASDAQ:NAMSW – Free Report) by 1.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 245,000 shares of the company’s stock after purchasing an additional 3,043 shares during the period. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $1,960,000 at the end of the most recent reporting period.
NewAmsterdam Pharma Stock Down 15.4%
Shares of NewAmsterdam Pharma stock traded down $3.69 on Wednesday, hitting $20.26. The stock had a trading volume of 1,013 shares, compared to its average volume of 538. NewAmsterdam Pharma has a one year low of $5.45 and a one year high of $29.99. The stock’s 50-day simple moving average is $25.72 and its two-hundred day simple moving average is $19.29.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.
The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.
Read More
- Five stocks we like better than NewAmsterdam Pharma
- This AI Opportunity Was Built to Evolve With Demand
- Punch these codes into your ordinary brokerage account
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Why Trump and Musk suddenly care about Fort Knox
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
